Updated on 4 July 2014
China has cracked down on high prices and corruption in the healthcare sector. Nonetheless, the revenue growth of publicly listed companies grew by nearly 22 percent.
Today, China accounts for nearly 50 percent share of the total market.
China's leading company Sinopharm alone is the size of combined revenue of India's publicly listed bioscience companies.
The top three companies contributed almost 62 percent share of the total revenue of China bioscience market.
China has almost eight companies which have over $1 billion in revenue.